Inhibitory effect of intravitreal injection of bevacizumab on nerve growth factor

Current Eye Research

Volumn 37, Issue 5, 2012, Pages 408-415

  Jee, Donghyun ^a   Lee, Won Ki ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Apoptosis; Bevacizumab; Nerve growth factor; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CASPASE 3; DNA FRAGMENT; MESSENGER RNA; NERVE GROWTH FACTOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; RETINA CELL; SHAM PROCEDURE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTRAVITREAL INJECTIONS; MALE; NERVE GROWTH FACTOR; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; RETINA; RETINAL NEOVASCULARIZATION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859913464     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.632108     Document Type: Article

References (46)

1. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853-865. (Pubitemid 32273121)
2. Sun Y, Jin K, Xie L et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003;111:1843-1851. (Pubitemid 38057729)
3. Levi-Montalcini R. The nerve growth factor 35 years later. Science. 1987;237:1154-1162. (Pubitemid 17124912)
4. Calza L, Giardino L, Giuliani A, Aloe L, Levi-Montalcini R. Nerve growth factor control of neuronal expression of angiogenetic and vasoactive factors. Proc Natl Acad Sci USA. 2001;98:4160-4165. (Pubitemid 32249915)
5. Hansen-Algenstaedt N, Algenstaedt P, Schaefer C et al. Neural driven angiogenesis by overexpression of nerve growth factor. Histochem Cell Biol. 2006;125:637-649. (Pubitemid 43780172)
6. Weinstein BM. Vessels and nerves: marching to the same tune. Cell. 2005;120:299-302. (Pubitemid 40222425)
7. Brouzas D, Charakidas A, Moschos M, Koutsandrea C, Apostolopoulos M, Baltatzis S. Bevacizumab (Avastin) for the management of anterior chamber neovascularization and neovascular glaucoma. Clin Ophthalmol. 2009;3:685-688.
8. Tao Y, Jonas JB. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. J Ocul Pharmacol Ther. 2010;26:207-212.
9. Ameri H, Chader GJ, Kim JG, Sadda SR, Rao NA, Humayun MS. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci. 2007;48:5708-5715. (Pubitemid 351260875)
10. Shahar J, Avery RL, Heilweil G et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (Philadelphia, Pa). 2006;26: 262-269. (Pubitemid 44318177)
11. Heiduschka P, Fietz H, Hofmeister S et al.; Tabingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823. (Pubitemid 351261238)
12. Dib E, Maia M, Longo-Maugeri IM et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci. 2008;49:1097-1100.
13. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina (Philadelphia, Pa). 2006;26:257-261. (Pubitemid 44318176)
14. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina (Philadelphia, Pa). 2006;26:882-888. (Pubitemid 44547440)
15. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 2006;142:162-164. (Pubitemid 43946808)
16. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci. 2007;48: 1773-1781. (Pubitemid 351261365)
17. Avci B, Avci R, Inan UU, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci. 2009;50:3438-3446.
18. Saint-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on maller cells and photoreceptors. PLoS ONE. 2008;3:e3554.
19. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
20. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003;199:221-228. (Pubitemid 36176028)
21. Sung CH, Chuang JZ. The cell biology of vision. J Cell Biol. 2010;190:953-963.
22. Kim JH, Kim C, Kim JH et al. Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology. 2008;29:1131-1135.
23. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol. 2009;247:171-177.
24. Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288:371-378. (Pubitemid 29113511)
25. Fuh G, Wu P, Liang WC et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625-6631. (Pubitemid 43847597)
26. Lambiase A, Aloe L. Nerve growth factor delays retinal degeneration in C3H mice. Graefes Arch Clin Exp Ophthalmol. 1996;234 Suppl 1:S96-100.
27. Lenzi L, Coassin M, Lambiase A, Bonini S, Amendola T, Aloe L. Effect of exogenous administration of nerve growth factor in the retina of rats with inherited retinitis pigmentosa. Vision Res. 2005;45:1491-1500. (Pubitemid 40386723)
28. Sun XD, Zhang X, Xu X, Yu Z, Chen RJ. [Neuroprotection of nerve growth factor in experiment retinal detachment]. Zhonghua Yan Ke Za Zhi. 2003;39:303-307.
29. Sun X, Xu X, Wang F et al. Effects of nerve growth factor for retinal cell survival in experimental retinal detachment. Curr Eye Res. 2007;32:765-772. (Pubitemid 47450622)
30. Nguyen TL, Kim CK, Cho JH, Lee KH, Ahn JY. Neuroprotection signaling pathway of nerve growth factor and brain-derived neurotrophic factor against staurosporine induced apoptosis in hippocampal H19-7/IGF-IR [corrected]. Exp Mol Med. 2010;42:583-595.
31. Salis MB, Graiani G, Desortes E, Caldwell RB, Madeddu P, Emanueli C. Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hindlimb postischaemic recovery in mice. Diabetologia. 2004;47:1055-1063. (Pubitemid 38918165)
32. Ali TK, Al-Gayyar MM, Matragoon S et al. Diabetes-induced peroxynitrite impairs the balance of pro-nerve growth factor and nerve growth factor, and causes neurovascular injury. Diabetologia. 2011;54:657-668.
33. Lazarovici P, Marcinkiewicz C, Lelkes PI. Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des. 2006;12:2609-2622.
34. Lazarovici P, Gazit A, Staniszewska I, Marcinkiewicz C, Lelkes PI. Nerve growth factor (NGF) promotes angiogenesis in the quail chorioallantoic membrane. Endothelium. 2006;13:51-59.
35. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci. 2010;51:4569-4573.
36. Sornelli F, Lambiase A, Mantelli F, Aloe L. NGF and NGFreceptor expression of cultured immortalized human corneal endothelial cells. Mol Vis. 2010;16:1439-1447.
37. Julio-Pieper M, Lozada P, Tapia V et al. Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway. J Clin Endocrinol Metab. 2009;94:3065-3071.
38. Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, Le Bourhis X. Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer. 2010;9:157.
39. Nico B, Mangieri D, De Luca A et al. Nerve growth factor and its receptors TrkA and p75 are upregulated in the brain of mdx dystrophic mouse. Neuroscience. 2009;161:1057-1066.
40. Lin G, Shindel AW, Fandel TM, Bella AJ, Lin CS, Lue TF. Neurotrophic effects of brain-derived neurotrophic factor and vascular endothelial growth factor in major pelvic ganglia of young and aged rats. BJU Int. 2010;105:114-120.
41. Sanchez A, Wadhwani S, Grammas P. Multiple neurotrophic effects of VEGF on cultured neurons. Neuropeptides. 2010;44: 323-331.
42. Carmignoto G, Comelli MC, Candeo P et al. Expression of NGF receptor and NGF receptor mRNA in the developing and adult rat retina. Exp Neurol. 1991;111:302-311.
43. Hallbaak F, Backstram A, Kullander K, Ebendal T, Carri NG. Expression of neurotrophins and Trk receptors in the avian retina. The Journal of comparative neurology (J Comp Neurol.) 1996;364:664-676. (Pubitemid 26046016)
44. Yu CQ, Zhang M, Matis KI, Kim C, Rosenblatt MI. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci. 2008;49:3870-3878.
45. Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007;245:1837-1842. (Pubitemid 350154019)
46. Luthra S, Narayanan R, Marques LE et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina (Philadelphia, Pa). 2006;26:512-518. (Pubitemid 44620391)